Tagged with M&A

Pharma Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de Elizalde reveals the key pillars that will drive the affiliate to new heights. In Mexico, generics make up 79 percent…

Pharma Merck Czech Republic’s MD reveals his plan to double Merck operations within the next five years and talks about the impact of the recent acquisition of Sigma Aldrich on the Czech Republic. You’ve assumed position as Managing Director Merck Czech Republic just over one year ago; what was the strategy…

Pharma GEODIS MD Stéphanie Hervé speaks about the company’s consolidated pharmaceutical logistics market with the 2011 acquisition of pre-wholesaler Pharmalog as well as the recent acquisition of OHL in the United States, matching their ongoing ambition in the field of healthcare to maintain all requirements of quality, synergy of logistics expertise,…

Pharma Doppel has been selected as the nucleus for significant investments in the CDMO industry by PE firm Trilantic Capital Partners, according to recently hired CEO Giuseppe Cassisi, who shares the organization’s plans to invest in both greenfield facilities and M&A in the coming years. Italy’s pharmaceutical exports are growing faster than any other…

Pharma Giorgio Bruno, CEO of Recipharm Italy, gives an insight into the success factors of the CDMO, discusses the recent acquisition of Mitim, and explains how this acquisition helps Recipharm not only achieve their growth ambitions but also provide better services to its clients. You were appointed CEO of Recipharm Italy…

Pharma Pharmaceuticals Stéphane Bouchard reveals why BD’s pharmaceutical systems centre of excellence is based in France; BD’s increased strength in medical devices following the acquisition of CareFusion in 2015; and why cooperation and transparency between medical device and pharmaceutical companies is crucial. What role can BD, as one of the world’s leading companies specializing in medical devices,…

Pharma André Choulika, founder & CEO of Cellectis, reveals why the 21st century will be the century of gene editing and Cellectis will be one of the leaders of this revolution; how unlike many of their competitors, they are a gene editing company at the core and why the idea of…

Pharma The October 2015 merger between Houston, TX-based Cyberonics and Milan, Italy-based Sorin has led the creation of LivaNova, a medical device manufacturer active in the fields of cardiac surgery, neuromodulation and cardiac rhythm management. With three operating headquarters, France is home to the Cardiac rhythm management (CRM) division. Jean Luc…

Pharmaceuticals Marius Fourie highlights implications of the recent merger between the company’s two subsidiaries and the unparalleled levels of value and service the consolidated organization will offer. He also illustrates the affiliate’s strategies in navigating the country’s dual-model healthcare system and the ways in which effective education and training can benefit all stakeholders…

Pharma Bart van de Kerkhof highlights how Covidien’s acquisition will drive Medtronic to new heights thanks to a broader product portfolio. Medtronic is already piloting projects and cooperating with key stakeholders to increase cost-savings and shape the Dutch healthcare system of the future, based on evolving partnerships with all stakeholders, and practical…

Pharma Anna Van Poucke, Partner and Chairman at KPMG Healthcare in the Netherlands, explains how KPMG can helps its partners and clients move forward towards a better integrated, more efficient and smartly designed healthcare eco-system, while remaining at the forefront of the industry in terms of M&A, supply chain and cultural…

Pharma Dr. Giorgio Pisani, President and CEO of IBSA Italy, talks about his founding of the company in 2001 and its rapid growth in the market through a combination of organic growth and acquisitions, as well as the current direction of the IBSA group and his ambitions for the company in…